Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maplirpacept with Tafasitamab and Lenalidomide in R/R DLBCL
NCT05626322Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
A Phase 2 trial of maplirpacept in diffuse large B-cell lymphoma (DLBCL), sponsored by Pfizer. Started Aug 2023; status: terminated.
02
Drugs
maplirpacept
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05626322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626322.